Featuring presentation videos and accompanying slides: Sponsored by Bristol-Myers Squibb; Attendees were able to engage virtually with other Immuno-Oncology professionals from across the country and increase thier knowledge of myositis, uveitis, thyroiditis and gastrointestinal toxicities secondary to immunotherapy.
If you would like to attend a future event on this topic, please email our Customer Service Team or telephone 01732 897788. They will be happy to assist you.
3 hours Continuing Professional Development
An excellent opportunity to refresh your knowledge with a good balance between science and case studies. This dedicated forum focused on:
| 9:30 |
Introductions, instructions and chair’s opening remarks
Jacqui Warden, Oncology Advanced Nurse Practitioner, Oxford University Hospitals NHS Foundation Trust
|
| Treating adverse effects | |
| 9:40 |
Developing protocols and improving management of GI side effects
Dr Vincent Cheung, Consultant Gastroenterologist, Oxford University Hospitals NHS Foundation Trust
|
| Managing side effects | |
| 10:10 |
Assessing, triaging and treating immune-related musculoskeletal toxicities
Jacqui Warden, Oncology Advanced Nurse Practitioner, Oxford University Hospitals NHS Foundation Trust
|
| 10:40 |
Questions and answers with the speakers
|
| 10:50 |
Sponsored presentation from Bristol Myers Squibb
Jo Christon, Associate Director Field Access, Bristol Myers Squibb
|
| 10:55 |
Opportunity to meet Bristol Myers Squibb in the breakout rooms
In dedicated breakout rooms, you will have the opportunity to chat directly with Bristol Myers Squibb
|
| 11:05 |
Screen break
|
| 11:15 |
Interactive discussion: Benchmark your experience of assessing and managing toxicities
|
| 11:35 |
Feedback from interactive discussion on Benchmark your experience of assessing and managing toxicities
|
| Identifying toxicities | |
| 11:45 |
Assessing and managing inflammatory ocular complications secondary to immunotherapy
Dr Tasanee Braithwaite, Consultant Ophthalmologist, The Medical Eye Unit, Guy's and St Thomas' NHS Foundation Trust and School of Immunology and Honorary Senior Lecturer, Microbial Sciences, King’s College London
|
| 12:15 |
Recognising and treating endocrine toxicity secondary to IO
Dr Daniel Morganstein, Consultant Endocrinologist, Chelsea and Westminster Hospital NHS Foundation Trust
|
| 12:45 |
Questions and answers with the speakers
|
| 12:55 |
Chair’s closing remarks and close of online forum
|
Your confirmed speakers to date:
Jacqui works as an Advanced Nurse Practitioner at the Churchill Hospital in Oxford, running nurse-led clinics in renal, prostate and lung cancers for patients receiving Systemic Anti-Cancer Treatments (SACT). As a non-medical prescriber, Jacqui provides patients with a comprehensive review and support service during active treatment both in clinic and in the Oncology Day Treatment Unit. Jacqui is Team Leader for the Oxford SACT Specialist Nurse Team.
Dr Vincent Cheung is a Consultant Gastroenterologist at Oxford University Hospitals NHS Foundation Trust. He co-runs a tertiary GI liaison service for immune-related adverse events managing patients from the Oxford Cancer Centre and other regional centres. Having graduated from University of Cambridge, he trained in London and Oxford, and completed a fellowship at the Royal Free GI Neuroendocrine Tumour unit. His clinical interests are in GI irAEs, IBD and advanced endoscopy. He is accredited as a Bowel Cancer Screening colonoscopist. He completed research in immunotherapy-related GI and liver adverse events at Oxford and published this work in Gastroenterology, Gut, British Journal of Cancer and Frontline Gastroenterology.
Dr Daniel Morganstein is a Consultant Endocrinologist based at Chelsea & Westminster Hospital NHS Trust and Royal Marsden NHS Trust.
He is an Honorary Clinical Senior Lecturer at Imperial College He has particular interests in endocrine tumours, including neuroendocrine tumours, adrenal tumours and paragangliomas, thyroid cancer, including medullary thyroid cancer, as well as in the endocrine toxicities of cancer therapy especially immunotherapy.
He has further interests in the management of diabetes during cancer.
He has recent publications in these fields.
Past attendee feedback
‘Enjoyable, clear speakers, opportunity to ask questions, well organised easy to navigate’
Ashford and St Peters Hospital, Practical Management of Immuno-Oncology (IO) Side Effects, July 2022
‘A good mix of learning options and styles. Good interactive groups to share experience, a good way to benchmark own experience and services’
United Lincolnshire Hospitals NHS Trust, Practical Management of Immuno-Oncology (IO) Side Effects, July 2022
‘Well organised and wide range of interesting topics.’
Royal Surrey NHS Foundation Trust, Practical Management of Immuno-Oncology (IO) Side Effects, July 2022
‘Very interesting to hear about management of more uncommon side effects such as eye disease, muscoloskeltal problems’
Worcester Royal Hospital, Practical Management of Immuno-Oncology (IO) Side Effects, July 2022
“An excellent morning. Really enjoyed the balance between the (complex) science of checkpoint inhibitors and case studies that illustrated the importance of careful assessment and multi-professional working relationships.”
Somerset NHS Foundation Trust, Recognising and Treating IO Side Effects, November 2021
“Excellent, relevant, worthwhile and informative. The best online forum I have attended.”
University Hospitals Trust Sussex NHS Foundation Trust, Recognising and Treating IO Side Effects, November 2021
“Great session with experts who were knowledgeable and explained things very well.”
Worcester Acute NHS Trust, Recognising and Treating IO Side Effects, November 2021
“Excellent. One of the best I've attended. Pitched perfectly and I understood it!”
West Hertfordshire Hospitals NHS Trust, Recognising and Treating IO Side Effects, July 2021
“I found it very friendly, and very informative. It was nice to talk to other areas before the presentations started in small groups and learn a bit about how other areas process are for triage and assessment of their patients.”
Sheffield Teaching Hospitals NHS Foundation Trust, Recognising and Treating IO Side Effects, July 2021
“I am so grateful for the knowledge acquired through my first virtual conference. It was very well organised with technical support provided, very efficient. Speakers were excellent and content very appropriate and relevant.”
Royal Surrey NHS Foundation Trust, Managing Side Effects of Cancer Immunotherapy, December 2020
“Informative, friendly and highly appropriate content. Really exciting day as it felt like networking and being present at a physical conference, so thank you for making it so warm and welcoming.”
Western Sussex Hospitals NHS Trust, Managing Side Effects of Cancer Immunotherapy, December 2020
Pricing structure
Terms and conditions